Skip to main content

Eucure Says anti-CTLA-4 Antibody Effective in Early Tests

Beijing 's Eucure Biopharma reported "encouraging" results from an Australian Phase I trial of its anti-CTLA-4 antibody in patients with solid tumor cancers. YH001 was administered in combination with Junshi Biosciences' anti-PD-1 mAb, toripalimab injection (Tuoyi). In preclinical tests, YH001 outperformed Bristol-Myers Squibb's Yervoy, according to Eucure. Eucure is a division of Biocytogen, a China -US drug biotech discovery and early-stage development CRO. More details.... Stock Symbols: (HK: 1877; SHA: 688180) (NYSE: BMY) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.